跳至主要内容
临床试验/NCT05411484
NCT05411484进行中(未招募)2 期

Self-controlled, Single-site Trial Investigation of Laser Assisted Drug Delivery of NanoDOX®

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2023年11月29日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
进行中(未招募)
入组人数
10
试验地点
2
主要终点
Skin drug uptake

研究概览

简要总结

This is a self-controlled single-site study of healthy subjects receiving an ablative fractional CO2 (carbon dioxide) laser procedure followed by topical application of NanoDOX® Hydrogel (1% doxycycline). The study includes skin biopsies to evaluate the effects of NanoDOX® Doxycycline Monohydrate Gel on wound healing after the ablative laser procedure. Study subjects will be asked to do 2 visits of 4 hours in total over approximately 1 week. An optional third visit will take place approximately 6 weeks after Visit 1. In this study, 20 subjects are expected to enroll with a goal of 12 healthy subjects to enroll and complete the study.

详细描述

Effective topical delivery of any pharmaceutical agent requires small molecule drugs to penetrate the epidermis, yet the absorption of topical products through the epidermis is limited.

In this study, the investigators are looking for healthy volunteers who are eligible to help us to determine the safety and efficacy of ablative fractional laser therapy combined with NanoDOX. The investigators are doing the research to evaluate drug delivery of topical NanoDOX® Hydrogel following ablative fractional CO2 laser treatment and our secondary objective is to evaluate the efficacy of NanoDOX® for wound healing.

Subjects will have a screening visit to determine eligibility, 2 study visits when they will receive CO2 ablative fractional laser treatment, NanoDOX® Hydrogel application, and skin biopsies, and 1 optional study visit for wound healing assessment. Laser procedure will happen only during visit 1, visit 2 will happen 2 days after visit 1, and visit 3 will happen approximately 6 weeks after visit 1. In total, 7 skin biopsies will be performed.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject must be able and willing to provide written informed consent and comply with the requirements of the study protocol;
  • Subject must be able to read and understand English;
  • Any gender and any Fitzpatrick skin type;
  • Age equal to or greater than 18 years old;
  • Willing to sun protect treated area (sunscreen or cover the area with clothes) for the duration of enrollment in the study and 1 year after treatment.
  • Subjects must be willing to undergo skin biopsies

排除标准

  • Participation in another investigational drug or device clinical trial in the past 30 days;
  • Are pregnant or lactating;
  • History of allergic reaction to topical or local anesthesia;
  • History of allergic reaction to Doxycycline or other tetracyclines;
  • Regular intake of high doses of anti-inflammatory drugs (aspirin >81 mg/day, ibuprofen, corticosteroids, etc.) , immunosuppressive drugs or biologics;
  • Clinically significant abnormal findings or conditions which might, in the opinion of the Investigator, interfere with study evaluations or pose a risk to subject safety during the study;
  • Laser treatment in past six months; History of poor wound healing;
  • History of keloids; History of extreme photosensitivity;
  • History of severe hyperpigmentation; History of tattoos on thighs.

研究组 & 干预措施

Pilot Arm

Experimental

Self-controlled 12 healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel

干预措施: CO2 Ablative Fractional Laser (Device)

Pilot Arm

Experimental

Self-controlled 12 healthy subjects receiving an ablative fractional CO2 laser procedure followed by topical application of NanoDOX® Hydrogel

干预措施: NanoDOX® Hydrogel (Drug)

结局指标

主要结局

Skin drug uptake

时间窗: 3 days

The depth of drug uptake will be measured by histology analysis. To determine if ablative fractional laser therapy combined with NanoDOX® topical drug improves the depth of drug uptake, fluorescence microscopy will be used to measure the concentration of the drug inside the skin by the amount of fluorescence created by the drug will be quantified.

次要结局

  • Wound healing(6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dieter Manstein, MD

Principal Investigator

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验